Mediterranean-style Dietary Pattern (MDP), Mood and Anxiety

Depression, Anxiety Clinical Trial

— MediMood  

Official title:

MediMood: A Randomised Controlled Trial Investigating the Acute Impact of a Plant Based Mediterranean-style Dietary Pattern (MDP) on Mood, Anxiety and Cognition in UK Adults With Mild to Moderate Mental Health Complaints

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05927376
• Other study ID #: R211670
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 1, 2023
• Est. completion date: June 30, 2024

Study information

• Verified date: May 2024
• Source: University of East Anglia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Observational studies and a limited numbers of RCTs have observed that habitual Mediterranean-style dietary pattern (MDP) consumption is associated with improved mental health and cognition. Yet, its efficacy in a short-term has not been studied in well-controlled intervention settings.

MediMood is a cross-over RCT aiming to test whether a MDP can affect mood and anxiety following a meal (postprandial) and over 5-days in adults over 18 years with mild to moderate mental health problems relative to a Western diet (WD).

Description:

Depression, anxiety and age-related cognitive decline are leading global public health problems. A plant-based Mediterranean-style dietary pattern (MDP) includes olive oil as the main source of fat, fresh fruits, vegetables, seafood, legumes and nuts and a low consumption of red and processed meat, confectionary, and high-sugar drinks. A MDP promotes both physical and mental wellbeing and brain function. However, most studies to date have examined the impact of a MDP on health over months or years. As several underpinning biological mechanisms are likely to be responsive within hours or days, examining the short-term effect of a MDP on mental health outcomes is important. The overall goal of the present study is to understand the effects of a MDP on acute/sub-chronic brain health and its underpinning mechanisms.

MediMood is a randomised cross-over efficacy trial. Participants will be assigned to an isocaloric MDP and a Western diet (WD) for 5-days in a random order with a 4-week wash-out period. All foods, meal plans and detailed dietary instructions will be provided. In addition to the primary outcome measures (mood and anxiety), the impact of intervention on cognitive performance, sleep, cerebral blood flow (MRI) and a selection of biomarkers of brain function will be measured in biological samples over five days.

As low mood, anxiety and stress disorders affect daily functioning and reduce the quality of life significantly for many, the investigators believe the findings will have wide public health application.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 25
• Est. completion date: June 30, 2024
• Est. primary completion date: December 15, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female, aged 18 or above

• Is willing and able to comply with all study procedures, including changes in diets

• Has access to and able to use the internet/computer/tablet device

• Mild to moderate level of anxiety and/or depression symptoms, assessed by Generalised Anxiety disorder (GAD-7) score and Patient Health Questionnaire (PHQ-9), scores 5 to 14 on both questionnaires

• A habitual MEDAS score of = 7/14

• To be fluent in English

Exclusion Criteria:

• MEDAS score >7

• Vegan/vegetarian

• Allergies to one of the study components i.e. nuts, fish

• On antidepressant or antianxiety medication where dosage is likely to change over the next 3 month

• Factors precluding MRI scanning such as suffers from claustrophobia or has metal implants

• Not fluent in English

• Not agreement for the study team to contact the participants general practitioner about trial participation and screening results

• Not prepared to make changes to the diet for 10 days (2 x 5 day periods)

Related Conditions & MeSH terms

• Anxiety Disorders
• Depression, Anxiety

Intervention

Behavioral:
• Mediterranean diet
All foods, meal plans and instructions provided.
• Western diet
All foods, meal plans and instructions provided.

Locations

Country	Name	City	State
United Kingdom	University of East Anglia	Norwich	Norfolk

Sponsors (2)

Lead Sponsor	Collaborator
University of East Anglia	Newcastle University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in dietary behaviour	Through the Mediterranean Diet Adherence Screener (14 items food questionnaire, MEDAS) questionnaire, with a minimum score of 0 and a maximum of 14. A higher score indicates a higher diet quality which is a better outcome	Screening and 3 months upon the completion
Other	Change in plasma insulin	Measured using ELISA	Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Other	Change in plasma glucose	Measured by autoanalyser	Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Other	Change in plasma triglycerides	Measured by autoanalyser	Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Other	Change in plasma cortisol	Measured by autoanalyser	Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Other	Change in plasma brain derived neurotropic factor	Measured by ELISA	Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Other	Change in plasma serotonin	Measured by ELISA	Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Primary	Change in mood	Established by the Bond-Lader visual analogue scale (includes 16 items each having antonyms on two ends, on a scale of 1 to 100, 50 being the neutral point)	Baseline (morning of day 1), Postprandial (after lunch on Established by the Bond-Lader visual analogue scale (includes 16 items each having day 1), 24-hours (morning of day 2), day 5 (morning of day 6 upon completion of 5 full days intervention)
Primary	Change in anxiety	Established by the Profile of Mood States (includes 65 items on a 5 point Likert scale)	Baseline (morning of day 1), Postprandial (after lunch on day 1), 24-hours (morning of day 2), day 5 (morning of day 6 upon completion of 5 full days intervention)
Secondary	Change in cognitive performance	Established by a neuropsychological test battery (https://neuropsychology.online) which assesses the following measures; attention, motor function, executive function, episodic memory, impulse control, visuospatial function	Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Secondary	Cerebral blood flow	Measured using MRI	Postprandial day 1
Secondary	Change in blood pressure	Measurements of brachial artery blood pressure (both diastolic and systolic pressure)	Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Secondary	Change in gut microbiota speciation	Faecal samples will be analysed for the gut microflora using 16sRNA sequencing.	Baseline (morning of day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Secondary	Change in plasma short chain fatty acids (SCFA)	Acetate, propionate and butyrate	Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Secondary	Change in untargeted metabolomics	Analysed through faecal samples using 1H-NMR-based untargeted metabolomics approach.	Baseline (morning of day 1), Postprandial (after lunch on day 1), day 5 (morning of day 6 upon completion of 5 full days intervention)
Secondary	Habitual sleep quality profile assessed by the Pittsburgh Sleep Quality Index	The Pittsburgh Sleep Quality Index is a 10-items validated questionnaire, which is based on 'the last month'. It will be used to establish usual sleep habits (before the interventions) and to identify sleep disturbances if there is any.	Baseline (morning of day 1)
Secondary	Change in subjective sleep quantity	Assessed using the Karolinska Sleep Diary (KSD). The KSD is a series of questions, with 5 possible tick box options, which characterise the efficiency and the duration of last night's sleep.	Each morning, days 1-6
Secondary	Change in subjective sleep quality	Assessed using the Karolinska Sleepiness Scale (KSS). The KSS is a single item, 9-point scale, assessing the sleepiness level at a particular time of day.	Each morning, days 1-6
Secondary	Change in objective sleep quality	Assessed using the MotionWatch 8. The MotionWatch 8 is a medical-grade actigraphy watch which can be used to monitor sleep, circadian rhythm and physical activity. Its software (The Motion Ware) will provide two objective measures of sleep quality, namely sleep efficiency and sleep fragmentation.	Each morning, days 1-6
Secondary	APOE4 genotype status	Assessed through DNA genotyping	Baseline (day 1)
Secondary	Participants subjective overview of the intervention	Assessed through a non-validated single question	Upon completion of 5 full days